152751-57-0 | 2-Propen-1-amine, hydrochloride (1:1), polymer with 2-(chloromethyl)oxirane

Packsize	Purity	Availability	Price	Discounted Price
25mg		in stock	$45.00	$32.00
100mg		in stock	$120.00	$84.00
500mg		in stock	$357.00	$250.00
1g		in stock	$595.00	$417.00

Description

• Catalog Number: AB07963
• Chemical Name: 2-Propen-1-amine, hydrochloride (1:1), polymer with 2-(chloromethyl)oxirane
• CAS Number: 152751-57-0
• Molecular Formula: C6H12ClNO
• Molecular Weight: 149.6186
• MDL Number: MFCD09260188
• SMILES: ClCC1CO1.C=CCN

Computed Properties

• Complexity: 55.1
• Covalently-Bonded Unit Count: 3
• Heavy Atom Count: 10
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 2
• Undefined Atom Stereocenter Count: 1

Literature

• Effects of phosphate on vascular function under normal conditions and influence of the uraemic state.

  Cardiovascular research 20121001

• Npt2b deletion attenuates hyperphosphatemia associated with CKD.

  Journal of the American Society of Nephrology : JASN 20120928

• Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.

  Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20120901

• Spontaneous carbonate formation in an amorphous, amine-rich, polymeric drug substance: sevelamer HCl product quality.

  Journal of pharmaceutical sciences 20120801

• Phosphate binders in CKD: bad news or good news?

  Journal of the American Society of Nephrology : JASN 20120801

• Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20120801

• Effects of phosphate binders in moderate CKD.

  Journal of the American Society of Nephrology : JASN 20120801

• Case of proximal calciphylaxis with protein S deficiency, successfully treated with multimodality therapy.

  The Journal of dermatology 20120701

• Enhancement and restriction of chain motion in polymer networks.

  International journal of pharmaceutics 20120701

• Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study.

  Clinical nephrology 20120701

• Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.

  Clinical therapeutics 20120701

• [Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD].

  Clinical calcium 20120701

• [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].

  Clinical calcium 20120701

• Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.

  Clinical journal of the American Society of Nephrology : CJASN 20120601

• Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study.

  Nephrology (Carlton, Vic.) 20120501

• Potential influence of sevelamer hydrochloride on responsiveness to erythropoiesis-stimulating agents in haemodialysis patients.

  Nephrology (Carlton, Vic.) 20120301

• Mortality in kidney disease patients treated with phosphate binders: a randomized study.

  Clinical journal of the American Society of Nephrology : CJASN 20120301

• Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120201

• Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20120201

• Potential interaction between sevelamer and fat-soluble vitamins: a hypothesis.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20120201

• Role of uremic toxins and oxidative stress in the development of chronic kidney disease-mineral and bone disorder.

  Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20120101

• Effects of phosphonoformic acid and renagel on renal type IIa sodium-dependent phosphate cotransporter mRNA expression in hyperphosphatemia rats.

  Renal failure 20120101

• Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.

  International journal of biological sciences 20120101

• Assessment of phosphate binding by sevelamer carbonate powder for oral suspension mixed in foods.

  Nephrology nursing journal : journal of the American Nephrology Nurses' Association 20120101

• Multi-intervention management of calciphylaxis: a report of 7 cases.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20111201

• CKD-mineral and bone disorder: core curriculum 2011.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20111201

• C-reactive protein levels are associated with arterial media calcification in nondiabetic patients with end-stage renal disease on long-term hemodialysis.

  Clinical nephrology 20111201

• Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20111201

• Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost.

  Nephrology (Carlton, Vic.) 20111101

• The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20111101

• Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.

  Nephrology (Carlton, Vic.) 20111101

• Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?

  European review for medical and pharmacological sciences 20111101

• A study of maintenance therapy after intravenous maxacalcitol for secondary hyperparathyroidism.

  Clinical nephrology 20111001

• Effectiveness and cost-efficacy of phosphate binders in hemodialysis.

  Annals of nutrition & metabolism 20111001

• Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study.

  Hemodialysis international. International Symposium on Home Hemodialysis 20111001

• Pharmacology, efficacy and safety of oral phosphate binders.

  Nature reviews. Nephrology 20110906

• Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.

  Clinical journal of the American Society of Nephrology : CJASN 20110901

• A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum.

  Journal of the American Academy of Dermatology 20110801

• Diffuse uremic tumoral calcinosis in a patient on long-term hemodialysis.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110801

• Biomechanical properties of bones from rats treated with sevelamer.

  Collegium antropologicum 20110601

• Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.

  Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20110501

• The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110501

• Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20110501

• Is combined calcium/magnesium phosphate binder really noninferior to sevelamer hydrochloride?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110401

• Uremic toxins and oral adsorbents.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20110401

• Sevelamer use and incidence of peritonitis in peritoneal dialysis.

  Wiener klinische Wochenschrift 20110401

• Does the choice of phosphate binder affect trace element levels in chronic kidney disease patients treated by regular haemodialysis?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110301

• Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20110301

• Pharmacology of the phosphate binder, lanthanum carbonate.

  Renal failure 20110301

• Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.

  The Cochrane database of systematic reviews 20110216

• Sevelamer prescriptions after reporting of the Dialysis Clinical Outcomes Revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20110201

• Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20110201

• Development and validation of rapid ion-chromatographic method with conductivity detection for trace level determination of allylamine in sevelamer drug substances.

  Journal of pharmaceutical and biomedical analysis 20110105

• Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.

  Nephron. Clinical practice 20110101

• Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients.

  Nephron. Clinical practice 20110101

• Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.

  Kidney international 20110101

• Phosphate binder is not phosphate binder! Sevelamer may be different!

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110101

• Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder.

  Renal failure 20110101

• [Chronic kidney disease and atherosclerosis].

  Nihon rinsho. Japanese journal of clinical medicine 20110101

• Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial.

  Trials 20110101

• Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study.

  Clinical drug investigation 20110101

• Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?

  BMC nephrology 20110101

• [Effect of non-calcium-based phosphate binders on vascular calcifications in patients on hemodialysis: clinical experience and hypotheses].

  Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20110101

• [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].

  Wiadomosci lekarskie (Warsaw, Poland : 1960) 20110101

• Regression of vascular calcification in a patient treated with cinacalcet: a case report.

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20110101

• Levothyroxine and sevelamer: listen to the patient.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101

• Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4.

  International urology and nephrology 20101201

• Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20101101

• Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).

  Expert opinion on pharmacotherapy 20101101

• [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].

  Clinical calcium 20101101

• Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients.

  Journal of the Formosan Medical Association = Taiwan yi zhi 20100901

• Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100801

• Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

  Leukemia research 20100701

• Impact of phosphate binder type on coronary artery calcification in hemodialysis patients.

  Clinical nephrology 20100701

• Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.

  Pharmacotherapy 20100701

• [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality].

  Clinical calcium 20100701

• [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].

  Clinical calcium 20100701

• Homocysteine and folic acid levels in hemodialysis patients treated with sevelamer hydrochloride.

  Clinical nephrology 20100601

• Sevelamer carbonate. No better than sevelamer hydrochloride.

  Prescrire international 20100601

• Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.

  Clinical journal of the American Society of Nephrology : CJASN 20100501

• Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients.

  American journal of nephrology 20100501

• [Secondary osteoporosis UPDATE. Therapy for bone-mineral disease in CKD-5D patients].

  Clinical calcium 20100501

• Oral phosphate binders in patients with kidney failure.

  The New England journal of medicine 20100408

• Sevelamer 'carbonate': what's in a name?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100401

• Novel markers of left ventricular hypertrophy in uremia.

  American journal of nephrology 20100401

• New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

  Pediatric nephrology (Berlin, Germany) 20100401

• [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].

  Nephrologie & therapeutique 20100401

• Development and utility of a multi-dimensional grid to assess individual mineral metabolism control in hemodialysis patients: A potential aid for therapeutic decision making?

  Hemodialysis international. International Symposium on Home Hemodialysis 20100401

• Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20100401

• Phosphate binders in CKD: chalking out the differences.

  Pediatric nephrology (Berlin, Germany) 20100301

• Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients.

  Pediatric nephrology (Berlin, Germany) 20100201

• Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

  Clinical journal of the American Society of Nephrology : CJASN 20100201

• A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20100201

• Interventions for bone disease in children with chronic kidney disease.

  The Cochrane database of systematic reviews 20100120

• Sevelamer carbonate.

  The Annals of pharmacotherapy 20100101

• Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins.

  Clinical nephrology 20100101

• Ten-year experience with sevelamer and calcium salts as phosphate binders.

  Clinical journal of the American Society of Nephrology : CJASN 20100101

• The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20100101

• Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: results from the RISCAVID study.

  Journal of nephrology 20100101

• Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?

  Journal of nephrology 20100101

• Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia.

  Blood purification 20100101

• Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients.

  Nephron. Clinical practice 20100101

• A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice.

  Journal of nephrology 20100101

• [Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20100101

• Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia.

  Blood purification 20100101

• The control of hyperphosphatemia in renal failure: between vascular calcification and inflammation.

  Blood purification 20100101

• A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091201

• Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.

  Clinical journal of the American Society of Nephrology : CJASN 20091201

• Uremic toxins originating from colonic microbial metabolism.

  Kidney international. Supplement 20091201

• Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism.

  Kidney international. Supplement 20091201

• Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation.

  Kidney international. Supplement 20091201

• Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.

  Drugs 20091112

• The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091001

• Sevelamer versus calcium-based phosphate binders in chronic kidney disease: what should we conclude from the evidence to date?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091001

• Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20091001

• Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.

  Clinical nephrology 20091001

• A bitter pill to swallow.

  Clinical nephrology 20091001

• Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.

  Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20090901

• Sevelamer reduces the efficacy of many other drugs.

  Prescrire international 20090801

• Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols.

  Pediatric nephrology (Berlin, Germany) 20090701

• Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients.

  Hemodialysis international. International Symposium on Home Hemodialysis 20090701

• [Clinical aspect of recent progress in phosphate metabolism. Phosphate retension, a powerful risk factor for mortality in chronic kidney disease (CKD)].

  Clinical calcium 20090601

• [Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia].

  Clinical calcium 20090601

• Oral phosphate binders.

  Kidney international 20090501

• Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.

  Pharmacotherapy 20090501

• Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.

  British journal of pharmacology 20090401

• [Chronic kidney disease (CKD) and bone. Control of CKD-MBD from the viewpoint of the medical cost].

  Clinical calcium 20090401

• [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].

  Clinical calcium 20090401

• [Chronic kidney disease (CKD) and bone. Vascular calcification in CKD].

  Clinical calcium 20090401

• [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20090401

• Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090301

• The use of phosphate binders: data from contributors to the European Practice Database.

  Journal of renal care 20090301

• Update on the treatment of chronic kidney disease-mineral and bone disorder.

  Journal of renal care 20090301

• Oral phosphate binders for the management of serum phosphate levels in dialysis patients.

  Journal of renal care 20090301

• [Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].

  Clinical calcium 20090201

• [Management of hyperphosphatemia ; phosphate-binder].

  Clinical calcium 20090201

• [Use of phosphate binder in predialysis patients].

  Clinical calcium 20090201

• [Novel phosphate binders under development].

  Clinical calcium 20090201

• [To facilitate the compliance of phosphate binder for the control of hyperphosphatemia in chronic kidney disease patients].

  Clinical calcium 20090201

• The control of hyperphosphatemia in chronic kidney disease: which phosphate binder?

  The International journal of artificial organs 20090201

• Effect of sevelamer hydrochloride on bone in experimental uremic rats.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20090201

• Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090101

• Diaminobutane (DAB) dendrimers are potent binders of oral phosphate.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20090101

• Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090101

• Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients on sevelamer hydrochloride: which dialysate calcium concentration to use?

  Blood purification 20090101

• Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification.

  American journal of nephrology 20090101

• Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.

  Hormone research 20090101

• [Treating distal calciphylaxis with therapy associated with sevelamer and bisphosphonates].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101

• Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients.

  Internal medicine (Tokyo, Japan) 20090101

• [Multiple peritrochanteric and pubic calcifications in a young woman on hemodialysis with severe renal osteodystrophy successfully treated with sevelamer+cinacalcet+paracalcitol combination therapy].

  Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20090101

• Strategies to manage low-bone turnover.

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101

• Vascular calcification and QT interval in incident hemodialysis patients.

  Journal of nephrology 20090101

• Sevelamer restores bone volume and improves bone microarchitecture and strength in aged ovariectomized rats.

  Endocrinology 20081201

• The CARE-2 study results: setting the record straight.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081201

• Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20081201

• Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data.

  Kidney international. Supplement 20081201

• A review article: sevelamer hydrochloride and metabolic acidosis in dialysis patients.

  Cardiovascular & hematological disorders drug targets 20081201

• Progression of calcification in the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20081101

• Hyperphosphatemia in the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20081101

• Binder wars.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20081101

• Effects of treatment of renal osteodystrophy on bone histology.

  Clinical journal of the American Society of Nephrology : CJASN 20081101

• New strategies in treatment of mineral and bone disorders and associated cardiovascular disease in patients with chronic kidney disease.

  Recent patents on cardiovascular drug discovery 20081101

• Overcoming obstacles for adherence to phosphate binding medication in dialysis patients: a qualitative study.

  Pharmacy world & science : PWS 20081001

• Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081001

• Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results.

  Hemodialysis international. International Symposium on Home Hemodialysis 20081001

• Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080901

• Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children.

  Pediatric blood & cancer 20080701

• Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.

  Clinical journal of the American Society of Nephrology : CJASN 20080701

• Time-dependent effect of sevelamerHCl on the cardiovascular system.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080601

• Sevelamer.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080601

• A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20080601

• Buffering effects of calcium carbonate as clarified by sevelamer hydrochloride monotherapy.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20080601

• Lack of mortality benefit with sevelamer.

  Kidney international 20080501

• Lower gastrointestinal bleeding: association with Sevelamer use.

  World journal of gastroenterology 20080428

• Comparison of chronic renal failure rats and modification of the preparation protocol as a hyperphosphataemia model.

  Nephrology (Carlton, Vic.) 20080401

• Use of sevelamer hydrochloride as an oxalate binder.

  The Journal of urology 20080401

• Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20080401

• [Treatment of secondary hyperparathyroidism in renal insufficiency: role of calcitriol, sevelamer and cinacalcet].

  Revue medicale suisse 20080305

• Ectopic mineralization of connective tissue in Abcc6-/- mice: effects of dietary modifications and a phosphate binder--a preliminary study.

  Experimental dermatology 20080301

• K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients.

  Kidney international 20080301

• Phosphate binder choice in dialysis patients: a call for evidence-based rather than marketing-based clinical practice.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20080301

• A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20080301

• Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.

  Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20080301

• Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients.

  Journal of the American Society of Nephrology : JASN 20080201

• An economic evaluation of sevelamer in patients new to dialysis.

  Current medical research and opinion 20080201

• Block randomized trial evidencing lower mortality with sevelamer compared with calcium phosphate binder in incident dialysis patients.

  Kidney international 20080201

• Phosphate binders and timing of levothyroxine administration.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080101

• Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients.

  American journal of nephrology 20080101

• After several years of witchhunting, can calcium-based phosphate binding be released on probation?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080101

• Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients.

  Clinical journal of the American Society of Nephrology : CJASN 20080101

• The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study.

  Academic radiology 20080101

• Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.

  Drugs 20080101

• Calciphylaxis of both proximal and distal distribution.

  Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20080101

• Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.

  Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20080101

• Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. No good evidence to promote a general use of sevelamer.

  Kidney international 20080101

• Efficacy and side effects of sevelamer hydrochloride as sole phosphate binder in peritoneal dialysis patients with severe hyperphosphatemia.

  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20080101

• Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.

  Nephron. Clinical practice 20080101

• Preventive measures and new pharmacological approaches of calcium and phosphate disorders.

  Contributions to nephrology 20080101

• Endotoxin-binding affinity of sevelamer hydrochloride.

  American journal of nephrology 20080101

• Nonphosphate-binding effects of sevelamer--are they of clinical relevance?

  Seminars in dialysis 20080101

• Calcium and the saga of the binders: accumulating controversy, or building consensus?

  International urology and nephrology 20080101

• [Clinical advances in vascular calcification].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101

• [Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101

• [Phosphorus (P) chelant in dialysis: efficacy and cost. Peritoneal dialysis solutions].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101

• Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study.

  Nephron. Clinical practice 20080101

• Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films.

  Renal failure 20080101

• Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study.

  Artificial organs 20071201

• A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.

  Current medical research and opinion 20071201

• Survival in end stage renal disease: calcium carbonate vs. sevelamer.

  Journal of clinical pharmacy and therapeutics 20071201

• Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20071201

• [In-vitro study of the drug interactions between Miglitol, an alpha-glucosidase inhibitor, and adsorbents].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20071201

• CKD-MBD: impact on management of kidney disease.

  Clinical and experimental nephrology 20071201

• A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.

  Clinical nephrology 20071201

• Study probes best choice of drug to reduce phosphate in patients on dialysis.

  JAMA 20071107

• Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.

  Kidney international 20071101

• The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.

  Kidney international 20071101

• The details bedevil DCOR.

  Kidney international 20071101

• Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.

  Journal of pharmaceutical sciences 20071001

• Economic evaluation of sevelamer in patients with end-stage renal disease.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071001

• Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: a prospective observational study.

  Hemodialysis international. International Symposium on Home Hemodialysis 20071001

• Sevelamer: a promising but unproven drug.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071001

• Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071001

• Calcium and phosphorus control in patients undergoing hemodialysis: from the view-points of activities of daily living.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20071001

• Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.

  Expert opinion on emerging drugs 20070901

• Emerging drugs for hyperphosphatemia.

  Expert opinion on emerging drugs 20070901

• Hyperostosis with hyperphosphatemia and tumoral calcinosis: a case report.

  Pediatric nephrology (Berlin, Germany) 20070801

• Transient acid exposure increases sevelamer HCl phosphate binding.

  Journal of pharmaceutical sciences 20070801

• New medications which decrease levothyroxine absorption.

  Thyroid : official journal of the American Thyroid Association 20070801

• Sevelamer and extension studies.

  Kidney international 20070701

• Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20070601

• Does Sevelamer reduce mortality by slowing of progression of coronary calcification?

  Kidney international 20070601

• [Phosphate binder up to date].

  Clinical calcium 20070501

• Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20070401

• Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.

  The International journal of artificial organs 20070401

• Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.

  Kidney international 20070301

• Control of hyperphosphatemia beyond phosphate.

  Kidney international 20070301

• [Arteriosclerosis and vascular calcification in chronic kidney disease (CKD) patients].

  Clinical calcium 20070301

• [Relationship between sevelamer HCl and vascular calcification].

  Clinical calcium 20070301

• [How to reach and maintain the K/DOQI recommendations for bone and mineral metabolism in patients undergoing haemodialysis: an efficient strategy].

  Nephrologie & therapeutique 20070301

• Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients.

  Kidney international 20070201

• Potential usefulness of sevelamer hydrochloride to improve cardiac outcome in patients with coronary disease and normal renal function.

  Medical hypotheses 20070101

• Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy.

  Journal of the American Society of Nephrology : JASN 20070101

• Animal models--what they can tell us about vascular calcification in CKD.

  Seminars in dialysis 20070101

• Vascular calcification and disordered mineral metabolism in dialysis patients.

  Seminars in dialysis 20070101

• Vascular calcification--a new window on the cardiovascular system: role of agents used to manipulate skeletal integrity.

  Seminars in dialysis 20070101

• Final Word: The binders wars 2007-2017: 'The truth is out there somewhere...'.

  Seminars in dialysis 20070101

• Causes and consequences of increased arterial stiffness in chronic kidney disease patients.

  Kidney & blood pressure research 20070101

• Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels.

  Internal medicine (Tokyo, Japan) 20070101

• Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure.

  Nephron. Physiology 20070101

• Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.

  Journal of nephrology 20070101

• [Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20070101

• Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.

  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20070101

• Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources.

  Journal of nephrology 20070101

• Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.

  Recent patents on cardiovascular drug discovery 20070101

• [K-DOQI guidelines for calcium and phosphorus metabolism in chronic kidney disease: outcomes, compliance and new drugs for treatment].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20070101

• Pleiotropic effects of the non-calcium phosphate binder sevelamer.

  Kidney international. Supplement 20061201

• Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20061101

• Review of dialysate calcium concentration in hemodialysis.

  Hemodialysis international. International Symposium on Home Hemodialysis 20061001

• Emerging strategies for lowering serum phosphorous in patients with end-stage renal disease.

  Expert opinion on pharmacotherapy 20061001

• The safety of phosphate binders.

  Expert opinion on drug safety 20060901

• Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20060901

• Phosphate binders and management of hyperphosphataemia in end-stage renal disease.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060801

• Novel dosage forms and regimens for sevelamer-based phosphate binders.

  Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20060701

• Molecular modeling studies of the binding characteristics of phosphates to sevelamer hydrochloride--assessing a novel technique to reduce phosphates contamination.

  International journal of environmental research and public health 20060601

• Diarrhea induced by high doses of nicotinamide in dialysis patients.

  Kidney international 20060501

• Phosphate binders.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060415

• A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20060401

• Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.

  Nephrology (Carlton, Vic.) 20060401

• Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060301

• Sevelamer therapy for pediatric end-stage renal disease.

  Pharmacotherapy 20060301

• Effects of sevelamer and calcium on coronary artery calcification in patients new to dialysis: time for better controlled clinical trials.

  Kidney international 20060301

• Phosphate binders.

  The Medical letter on drugs and therapeutics 20060213

• Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.

  Kidney international 20060201

• Sevelamer hydrochloride in peritoneal dialysis patients: ca' canny but ca' awa'.

  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20060101

• Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients.

  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20060101

• Sevelamer worsens metabolic acidosis in hemodialysis patients.

  Journal of nephrology 20060101

• Long-term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients.

  Renal failure 20060101

• A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.

  Renal failure 20060101

• Hyperphosphatemia and phosphate binders.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20051115

• Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice.

  Circulation 20051101

• Drug interaction between sevelamer and furosemide.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20051001

• Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.

  Kidney international 20051001

• Gastric pH, sevelamer hydrochloride and omeprazole.

  Clinical nephrology 20051001

• The effect of sevelamer on tacrolimus target levels.

  Transplantation 20050915

• [Treatment of adynamic bone disease with the complete replacement from calcium carbonate to sevelamer hydrochloride].

  Clinical calcium 20050901

• [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].

  Clinical calcium 20050901

• [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].

  Clinical calcium 20050901

• [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].

  Clinical calcium 20050901

• [Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism].

  Clinical calcium 20050901

• [Control of calcium and phosphate in hemodialysis patients].

  Clinical calcium 20050901

• [Relationship between serum calcium level and PTH concentration proved with sevelamer hydrochloride].

  Clinical calcium 20050901

• [Clinical effect of introduction of sevelamer hydrochloride in patients with hyperphosphatemia undergoing maintenance dialysis].

  Clinical calcium 20050901

• [Sevelamer hydrochloride and K/DOQI guidelines].

  Clinical calcium 20050901

• [Sevelamer hydrochloride and vitamin D for controlling serum calcium, phosphorus and bone metabolism in patients undergoing hemodialysis].

  Clinical calcium 20050901

• [Role of sevelamer hydrochloride in the Coronary Artery Calcification Index].

  Clinical calcium 20050901

• [Management of secondary hyperparathyroidism].

  Clinical calcium 20050901

• [Present status and problems in vitamin D and sevelamer therapy (discussion)].

  Clinical calcium 20050901

• Length of interdialytic interval influences serum calcium and phosphorus concentrations.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050801

• Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050801

• Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.

  Journal of the American Society of Nephrology : JASN 20050801

• Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801

• Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801

• Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801

• Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801

• Introduction to sevelamer hydrochloride and its clinical effects.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801

• Role of sevelamer hydrochloride in the coronary artery calcification score.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801

• Impact of sevelamer hydrochloride and the K/DOQI guidelines.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050801

• [Pharmacologic intervention for vascular calcification].

  Clinical calcium 20050701

• Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis.

  Kidney international. Supplement 20050601

• End stage renal disease.

  Clinical evidence 20050601

• Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20050501

• Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.

  American heart journal 20050501

• New strategy to attenuate pulse wave velocity in haemodialysis patients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050401

• Economic impact of sevelamer in patients with ESRD.

  Kidney international 20050401

• Opportunity and cost of sevelamer in dialysis patients.

  Kidney international 20050401

• K/DOQI practice guidelines for bone metabolism and disease in chronic kidney disease: another opportunity for renal dietitians to take a leadership role in improving outcomes for patients with chronic kidney disease.

  Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20050401

• The therapeutic potential of novel phosphate binders.

  Pediatric nephrology (Berlin, Germany) 20050301

• Sevelamer and pharmacokinetics of cyclosporin A after kidney transplantation.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050301

• Drug interaction between sevelamer and cyclosporin.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050301

• Sevelamer-induced acidosis.

  Kidney international 20050201

• Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050201

• The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050201

• Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050201

• Different routes bridging calcium in Japanese hemodialysis patients.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20050201

• [Sevelamer:hydrochloride].

  Clinical calcium 20050101

• Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.

  Arthritis and rheumatism 20050101

• Phosphorus management in end-stage renal disease.

  Seminars in dialysis 20050101

• Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride.

  Renal failure 20050101

• Cardiovascular calcification progression -- a comparison of sevelamer and calcium-based phosphate binders.

  Blood purification 20050101

• The clinical management of hyperphosphatemia.

  Journal of nephrology 20050101

• [New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20050101

• Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.

  Renal failure 20050101

• Effects of efficient phosphate binding on bone in chronic renal failure rats.

  Renal failure 20050101

• A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients.

  Nephron. Clinical practice 20050101

• Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride.

  International urology and nephrology 20050101

• Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20050101

• Peritoneal dialysis patients using sevelamer do not present the acidosis problems that hemodialysis patients do.

  Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 20050101

• Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.

  Nephrology (Carlton, Vic.) 20041201

• The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20041001

• [New aspects in the management of renal osteodystrophy].

  Polskie Archiwum Medycyny Wewnetrznej 20041001

• Pathophysiology of vascular calcification in chronic kidney disease.

  Circulation research 20040917

• Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications.

  Kidney international. Supplement 20040901

• A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States.

  Kidney international 20040901

• [Prophylaxis and treatment of adynamic bone].

  Clinical calcium 20040901

• [Evolution in vitamin D treatment after debut of sevelamer hydrochloride in chronic renal failure patients].

  Clinical calcium 20040901

• Phosphate binders in dialyzed patients: efficacy and cost.

  Pediatric nephrology (Berlin, Germany) 20040801

• Vascular calcification in patients with end-stage renal disease.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040801

• Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.

  Clinical nephrology 20040801

• Dietary phosphorus reduction by pretreatment of human breast milk with sevelamer.

  Pediatric nephrology (Berlin, Germany) 20040701

• Drug interaction between sevelamer and cyclosporin.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040701

• The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.

  Current medical research and opinion 20040701

• Determination of the binding parameter constants of Renagel capsules and tablets at pH 7 by high performance capillary electrophoresis.

  Journal of pharmaceutical and biomedical analysis 20040629

• Determinants of progressive vascular calcification in haemodialysis patients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040601

• Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.

  Saudi medical journal 20040601

• [Treatment for chronic kidney failure with cerebrovascular disease].

  Nihon rinsho. Japanese journal of clinical medicine 20040601

• [Ischemic heart disease].

  Nihon rinsho. Japanese journal of clinical medicine 20040601

• [Evaluation of coronary artery calcification in ESRD patients].

  Clinical calcium 20040601

• [Sevelamer hydrochloride prevents ectopic calcification of blood vessels].

  Clinical calcium 20040601

• Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).

  Kidney international 20040501

• [Phosphate binding therapy].

  Nihon rinsho. Japanese journal of clinical medicine 20040501

• [Outlines of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease].

  Clinical calcium 20040501

• [Treatment of bone disease in chronic kidney disease and in renal transplant recipients under K/DOQI clinical practice guidelines].

  Clinical calcium 20040501

• [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].

  Clinical calcium 20040501

• [Mechanism and therapy of vascular calcification].

  Clinical calcium 20040501

• [Front line of management of hyperphosphatemia in hemodialysis patients].

  Clinical calcium 20040501

• Nephrogenic fibrosing dermopathy in pediatric patients.

  Pediatric nephrology (Berlin, Germany) 20040401

• Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20040301

• Improving phosphate-binder therapy as a way forward.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040301

• Drug interaction between sevelamer and cyclosporin.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20040201

• [Skeletal complications of renal insufficiency].

  Nihon rinsho. Japanese journal of clinical medicine 20040201

• An unusual case of calciphylaxis.

  Journal of cutaneous medicine and surgery 20040101

• Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.

  Nephron. Clinical practice 20040101

• [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20040101

• Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure.

  Seminars in dialysis 20040101

• Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.

  Pediatric nephrology (Berlin, Germany) 20031201

• Sevelamer: where are the data?

  Kidney international 20031201

• Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20031201

• Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.

  Kidney international 20031101

• [Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20031101

• Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20031001

• Calcium-containing phosphate binder use associated with accelerated atherosclerotic coronary calcification.

  Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20031001

• Slowing the progression of vascular calcification in hemodialysis.

  Journal of the American Society of Nephrology : JASN 20030901

• Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats.

  Kidney international 20030801

• Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.

  Current opinion in nephrology and hypertension 20030701

• Prevention and treatment of secondary hyperparathyroidism: still a challenge for the nephrologist?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030701

• Hyperphosphataemia and treatment with sevelamer in haemodialysis patients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030701

• Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate.

  Kidney international. Supplement 20030601

• Medical management of secondary hyperparathyroidism in chronic renal failure.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030601

• Sevelamer hydrochloride, a calcium-free phosphate binder, inhibits parathyroid cell proliferation in partially nephrectomized rats.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030601

• Phosphate binder usage in kidney failure patients.

  Expert opinion on pharmacotherapy 20030601

• A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies.

  Clinical nephrology 20030601

• Management of hyperphosphataemia in chronic renal disease: lessons from the past and future directions.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030401

• The renal dietitian's role in managing hyperphosphatemia and secondary hyperparathyroidism in dialysis patients: a national survey.

  Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20030401

• Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.

  Advances in renal replacement therapy 20030401

• Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030301

• New strategies for the treatment of secondary hyperparathyroidism.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20030301

• Calcium on trial: beyond a reasonable doubt?

  Kidney international 20030101

• Calcium on trial: beyond a reasonable doubt?

  Kidney international 20030101

• Hyperphosphataemia in renal failure: causes, consequences and current management.

  Drugs 20030101

• [Critical appraisal of sevelamer for the treatment of hyperphosphatemia in patients with chronic renal failure].

  Revista da Associacao Medica Brasileira (1992) 20030101

• [Management of hyperphosphoremia].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20030101

• Sevelamer.

  Nephron. Clinical practice 20030101

• The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients.

  American journal of nephrology 20030101

• Safety of new phosphate binders for chronic renal failure.

  Drug safety 20030101

• [Experience with sevelamer in peritoneal dialysis].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20030101

• Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.

  Journal of nephrology 20030101

• Oral calcium, sevelamer and vascular calcification in uraemic patients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20021201

• Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients.

  Nephron 20021001

• Effect of phosphate binders on supplemental iron absorption in healthy subjects.

  Journal of clinical pharmacology 20021001

• The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.

  Journal of the American Society of Nephrology : JASN 20020901

• A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020901

• Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care.

  Clinical nephrology 20020901

• Bile acid binding to sevelamer HCl.

  Kidney international 20020801

• Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.

  Kidney international 20020701

• Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography.

  Journal of pharmaceutical and biomedical analysis 20020620

• The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020201

• Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020101

• Sevelamer, a phosphate-binding polymer, is a non-absorbed compound.

  Clinical pharmacokinetics 20020101

• RenaGel efficacy in severe secondary hyperparathyroidism.

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20020101

• Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients.

  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20020101

• Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder.

  Nephron 20011101

• Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010901

• Sevelamer, Ca x P product and vitamin D.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010201

• Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics.

  Journal of clinical pharmacology 20010201

• Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers.

  Journal of clinical pharmacology 20010201

• Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.

  Journal of nephrology 20010101